Overview

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

Status:
Completed

Trial end date:
2013-01-07

Target enrollment:

Participant gender:

Summary

A phase IV, prospective, multicenter , randomized open label, 48 weeks study to evaluate the antiretroviral efficacy and safety of atazanavir/ritonavir or darunavir/ritonavir, each in combination with a fixed dose of tenofovir disoproxil fumarate- emtricitabine in HIV-1-infected treatment-naïve subjects with CD4 counts below 200 µL.

Phase:

Phase 4

Details

Lead Sponsor:

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Treatments:

Atazanavir Sulfate
Darunavir